Brent Saunders, Bausch + Lomb CEO (Richard Drew/AP Images)
May 18, 2023 03:28 PM EDTUpdated 03:59 PM
Pharma
FDA+

Bausch + Lomb and No­valiq win ap­proval for dry eye dis­ease treat­ment

Nicole DeFeudis

Editor

Bausch + Lomb and No­valiq se­cured an ap­proval for their dry eye dis­ease drop on Thurs­day, to be mar­ket­ed as Miebo.

The drug, al­so known as …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Pfiz­er ends roll­out of Be­qvez, putting an­oth­er dent in he­mo­phil­ia gene ther­a­py field

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times